Immunome Net Income From Continuing Ops from 2010 to 2026
| IMNM Stock | USD 24.00 2.41 9.13% |
Net Loss | First Reported 2019-09-30 | Previous Quarter -43.4 M | Current Value -57.5 M | Quarterly Volatility 33.7 M |
Check Immunome financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immunome's main balance sheet or income statement drivers, such as Net Interest Income of 15.5 M, Interest Income of 15.5 M or Depreciation And Amortization of 2.5 M, as well as many indicators such as Price To Sales Ratio of 33.61, Dividend Yield of 0.0 or PTB Ratio of 3.25. Immunome financial statements analysis is a perfect complement when working with Immunome Valuation or Volatility modules.
Immunome | Net Income From Continuing Ops | Build AI portfolio with Immunome Stock |
Evaluating Immunome's Net Income From Continuing Ops across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Immunome's fundamental strength.
Latest Immunome's Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of Immunome over the last few years. It is Immunome's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Immunome's overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
Immunome Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | (63,200,710) | |
| Coefficient Of Variation | (160.46) | |
| Mean Deviation | 77,778,380 | |
| Median | (7,845,000) | |
| Standard Deviation | 101,410,786 | |
| Sample Variance | 10284.1T | |
| Range | 285.1M | |
| R-Value | (0.75) | |
| Mean Square Error | 4836.2T | |
| R-Squared | 0.56 | |
| Significance | 0.0006 | |
| Slope | (15,016,561) | |
| Total Sum of Squares | 164546.4T |
Immunome Net Income From Continuing Ops History
About Immunome Financial Statements
Immunome investors utilize fundamental indicators, such as Net Income From Continuing Ops, to predict how Immunome Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Loss | -263.7 M | -250.5 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out the analysis of Immunome Correlation against competitors. To learn how to invest in Immunome Stock, please use our How to Invest in Immunome guide.You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Will Biotechnology sector continue expanding? Could Immunome diversify its offerings? Factors like these will boost the valuation of Immunome. Market participants price Immunome higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Immunome data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (2.90) | Revenue Per Share | Quarterly Revenue Growth 0.698 | Return On Assets | Return On Equity |
Understanding Immunome requires distinguishing between market price and book value, where the latter reflects Immunome's accounting equity. The concept of intrinsic value - what Immunome's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Immunome's price substantially above or below its fundamental value.
Please note, there is a significant difference between Immunome's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunome is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Immunome's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.